ICON PLC (NASDAQ:ICLR) had its price objective lifted by analysts at Mizuho from $104.00 to $108.00 in a research note issued on Thursday. The firm presently has a “neutral” rating on the medical research company’s stock. Mizuho’s price target indicates a potential upside of 5.02% from the stock’s current price.
Other analysts have also recently issued research reports about the stock. Robert W. Baird cut their price target on shares of ICON PLC from $107.00 to $97.00 and set an “outperform” rating for the company in a research note on Friday, June 9th. BidaskClub raised shares of ICON PLC from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Jefferies Group LLC raised shares of ICON PLC from a “hold” rating to a “buy” rating and increased their price objective for the company from $86.00 to $117.00 in a research report on Thursday, June 29th. Goldman Sachs Group, Inc. (The) raised shares of ICON PLC from a “buy” rating to a “conviction-buy” rating and set a $117.00 price target on the stock in a research report on Friday, July 7th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $102.00 price target (up from $91.00) on shares of ICON PLC in a research report on Tuesday, June 6th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. ICON PLC has an average rating of “Buy” and an average target price of $102.63.
ICON PLC (NASDAQ ICLR) traded down 2.83% during trading on Thursday, reaching $102.84. 932,831 shares of the company were exchanged. ICON PLC has a 52-week low of $73.76 and a 52-week high of $107.72. The firm has a market cap of $5.53 billion, a price-to-earnings ratio of 20.86 and a beta of 0.59. The firm has a 50-day moving average of $97.95 and a 200-day moving average of $87.43.
ICON PLC (NASDAQ:ICLR) last announced its earnings results on Thursday, July 27th. The medical research company reported $1.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.01. ICON PLC had a net margin of 15.97% and a return on equity of 29.24%. The business had revenue of $431 million during the quarter, compared to analysts’ expectations of $430.68 million. During the same quarter in the prior year, the company posted $1.14 earnings per share. The firm’s revenue was up 5.0% on a year-over-year basis. On average, equities analysts forecast that ICON PLC will post $5.23 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2017/07/29/icon-plc-nasdaqiclr-pt-raised-to-108-00.html.
A number of institutional investors have recently bought and sold shares of the company. Legato Capital Management LLC increased its position in ICON PLC by 7,872.0% in the first quarter. Legato Capital Management LLC now owns 6,078,411 shares of the medical research company’s stock worth $76,247,000 after buying an additional 6,002,164 shares in the last quarter. WCM Investment Management CA increased its position in shares of ICON PLC by 5.1% in the first quarter. WCM Investment Management CA now owns 3,712,253 shares of the medical research company’s stock worth $295,941,000 after buying an additional 180,896 shares during the period. Wellington Management Group LLP increased its position in shares of ICON PLC by 0.5% in the first quarter. Wellington Management Group LLP now owns 3,596,168 shares of the medical research company’s stock worth $286,687,000 after buying an additional 17,609 shares during the period. Alliancebernstein L.P. increased its position in shares of ICON PLC by 6.4% in the first quarter. Alliancebernstein L.P. now owns 2,987,617 shares of the medical research company’s stock worth $238,173,000 after buying an additional 178,995 shares during the period. Finally, FMR LLC increased its position in shares of ICON PLC by 9.2% in the first quarter. FMR LLC now owns 1,655,055 shares of the medical research company’s stock worth $131,941,000 after buying an additional 139,222 shares during the period. 92.61% of the stock is currently owned by hedge funds and other institutional investors.
ICON PLC Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for ICON PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON PLC and related companies with MarketBeat.com's FREE daily email newsletter.
